NEW LEAF VENTURES Aktie

 

Series C financing led by NEA, joined by new investor Foresite Capital and Abcuro's existing investors Proceeds to support completion of the registrational Phase 2/3 MUSCLE trial of ulviprubart in inclusion body myositis, BLA filing, and commercial launch preparation NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the closing of a $200 million Series C financing led by New Enterprise Associates (NEA) with Foresite Capital joining the round and participation of existing investors including RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, funds managed by abrdn Inc., funds and accounts managed by BlackRock, Eurofarma Ventures, and Soleus Capital. Proceeds from the Series C financing will be used to complete the registratio...